Company Overview

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s targeting accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who may not previously have been considered radiation therapy candidates. ViewRay believes MRIdian may improve the safety and efficacy of radiation therapy, potentially leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Financial News

Date Title and Summary Additional Formats
Toggle Summary ASTRO 2020 to Feature Latest MRIdian Clinical Experience Highlighting Outcomes in Tough to Treat Cancer
Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions CLEVELAND , Oct. 21, 2020 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian® Linac MRI-guided radiation therapy system will be featured at the 2020 Annual Meeting of the
Toggle Summary ViewRay Announces Conference Call for Third Quarter 2020 Financial Results to be Held After Market on November 5, 2020
CLEVELAND , Oct. 15, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its third quarter 2020 financial results.     ViewRay will hold a conference call to discuss results on Thursday, November 5, 2020 at 4:30 p.m. ET / 1:30 p.m. PT .
Toggle Summary Louis Stokes Cleveland VA Medical Center Purchases ViewRay's MRIdian Linac for MRI-Guided Radiation Therapy
MRIdian to Bring Benefits of MRI-Guided Radiation Therapy to Veterans Throughout Ohio and the Surrounding Region CLEVELAND , Oct. 14, 2020 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today that the Louis Stokes Cleveland VA Medical Center in Cleveland, Ohio has purchased the MRIdian ®
Toggle Summary ViewRay to Host Physician-led Webinar for Investors and Analysts at the 2020 American Society of Radiation Oncology (ASTRO) Annual Meeting
CLEVELAND , Oct. 1, 2020 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced that the Company will host a virtual physician-led informational discussion for investors and analysts during the 2020 American Society of Radiation Oncology (ASTRO) Annual Meeting.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449

In Need of Customer Support? Contact

  Language Select